Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 2;54(8):1841–1852.e4. doi: 10.1016/j.immuni.2021.06.015

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Author(s)

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Durable neutralizing antibody response to original virus strain in COVID-19 convalescent individuals

(A) Participant demographics and clinical characteristics for cross-sectional blood samples are summarized: number of individuals in each severity group, age, body mass index (BMI), percentage of gender, smoking, and morbidity (HT, hypertension; DM, diabetes mellitus; DL, dyslipidemia), and date of symptom onset. All individuals were confirmed positive via PCR and seropositive via the detection of anti-nucleocapsid antibodies (Roche kit) and provided blood samples up to three times.

(B) ROC curve for RBD IgG titers of 368 convalescent plasma samples and 19 pre-pandemic negative samples. Area under the curve (AUC) and 95% confidence interval (CI) are indicated.

(C and D) Cross-sectional RBD IgG titers (C) and pseudovirus neutralizing antibody (VSV NT) titers (D) from COVID-19 convalescent plasma samples (n = 368). Dashed lines indicate the cut-off determined by ROC analysis.